“We also found that receipt of an additional booster dose of vaccine was associated with a 50% reduction in adjusted odds of severe disease,” noted Dr. Branch-Elliman.
Dr. Nori emphasized that, given these data, emphatic messaging is needed to encourage uptake of the updated Omicron-targeted vaccines for these high-risk age groups.
The study by Dr. Chalkias and colleagues was funded by Moderna. Dr. Chalkias and several coauthors are employed by Moderna. One coauthor has relationships with DLA Piper/Medtronic, and Gilead Pharmaceuticals, and one has relationships with Celgene/Bristol-Myers Squibb, ChemoCentryx, Gilead, and Kiniksa. Dr. Nori has disclosed no relevant financial relationships.
A version of this article first appeared on Medscape.com.